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Birth size has been positively associated with age at menarche and height in adolescence and adulthood, but the relevant biological
mechanisms remain unclear. Among 262 Norwegian term-born singleton girls, birth size measures (weight, length, ponderal index,
head circumference and subscapular skin-fold thickness) were analysed in relation to adolescent hormone levels (oestradiol, prolactin,
dehydroepiandrosterone sulphate, androstenedione and free testosterone index), age at menarche and adolescent (ages 12.7–15.5
years) and body size (height, weight, body mass index and waist-to-hip ratio) using survival analysis and general linear modelling. The
results were adjusted for gestational age at birth, age and menarcheal status at measurement in adolescence and maternal age at
menarche. Birth weight, birth length and head circumference were positively associated with adolescent weight and height, and small
birth size was associated with earlier age at menarche. Subscapular skin-fold thickness at birth was not associated with adolescent
body size, but low fold-thickness was associated with earlier age at menarche. Measures of birth size were inversely related to
circulating levels of dehydroepiandrosterone sulphate in adolescence, but there was no clear association with other hormones. These
results suggest that physical and sexual development in puberty and adolescence is influenced by prenatal factors, and in combination,
these factors may influence health and disease later in life.
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The hypothesis that breast cancer (BC) may originate in utero
(Trichopoulos, 1990) has stimulated studies of birth size in
relation to risk factors for BC (Okasha et al, 2003). Birth size is an
indicator of foetal growth and may reflect intrauterine exposure to
oestrogen, the key factor that was originally proposed to explain a
possible association between intrauterine factors and adult BC
(Trichopoulos, 1990). Studies have shown that relatively large birth
size is associated with later age at menarche (Adair, 2001; Sloboda
et al, 2007) and taller body height, both in adolescence (Pietila ¨inen
et al, 2001; Romundstad et al, 2003) and in adulthood (Loos et al,
2002). Adult tallness is associated with higher BC risk, and the
positive association between birth size and body height suggests
that longitudinal growth in childhood and adolescence may be
important determinants for subsequent BC (Michels and Willett,
2004). Birth size has also been inversely related to adrenal
androgen production during childhood (Ong et al, 2004) and
adolescence (Ibanez et al, 1999). Adult levels of both adrenal and
gonadal androgens have been associated with BC risk (Kaaks et al,
2005a,b). The fact that small birth size is associated with earlier
age at menarche and higher circulating levels of adrenal androgens
cannot be easily reconciled with known BC risk factors, as small
birth size may be related to reduced risk, and both early age at
menarche and androgens are expected to increase risk.
We have examined the relation between birth size characteristics
and potential BC risk factors (ESHRE Capri Workshop Group,
2004), and specifically the association with age at menarche and
height and weight in adolescence, as well as with circulating levels
of prolactin, androgens and oestradiol.
MATERIALS AND METHODS
The study is based on the Norwegian part of an international study
among pregnant women in 1985–1986, described in detail
elsewhere (Bakketeig et al, 1993). Briefly, Caucasian women with
one or two singleton births were included. Of these, two groups
were followed in detail throughout pregnancy and their children
extensively examined at birth, one of a 10% random sample
(n¼561) of all women; the other group of women with one or
more of the following risk factors for giving birth to a small birth
size for gestational age child (SGA, i.e., in the 10% lowest birth
weights for known gestational age): a previous low-birth-weight
child or perinatal death, cigarette smoking at conception, Revised 2 May 2008; accepted 12 May 2008; published online 1 July 2008
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ypre-pregnancy weight below 50kg, chronic renal disorder or
hypertension (n¼1384).
In 2001–2002, girls born in the original study were invited to a
follow-up examination in adolescence. Among a total of 523
invited girls, 146 were excluded because they were not born at term
(before week 37 or after week 42) or because exact gestational age
was missing. In addition, 39 girls were excluded either because
they had died (n¼5), were reluctant to participate (n¼8) or gave
practical reasons (n¼26). Of the remaining 338 invited girls, 262
attended the follow-up examination (77.6%). Mean age at
examination in adolescence was 14.0 years (range 12.7–15.5
years). The examination included anthropometric measurements,
serum samples and a questionnaire related to health and life style
factors, pubertal development and menstrual status. The study was
approved by the Regional Committee for Medical Research Ethics
and by the Norwegian Data Inspectorate.
Birth size measurements included length (crown to heel, to the
nearest half, cm), weight (in g), ponderal index (weight/length
3,i n
gcm
 3), head circumference (in mm) and subscapular skin-fold
thickness (10th of a millimetre after 60s using a Harpenden
calliper, placed below the inferior angle of the left scapula). Each
measure was categorised into three groups of similar size (tertiles).
Information on maternal age at menarche (years) and gestational
age at delivery (days) was collected at birth.
Birth size measurements were analysed in relation to the
measures of adolescent body size (height, weight, body mass index
(BMI) and waist-to-hip ratio) age at menarche and to adolescent
levels of oestradiol, prolactin, dehydroepiandrosterone sulphate
(DHEAS), androstenedione and also free testosterone index (FTI),
calculated as (total testosterone/SHBG) 100. Analyses of DHEAS
and prolactin were carried out in all girls, regardless of menstrual
status, but for oestradiol, androstenedione and FTI were restricted
to those in the follicular phase of their menstrual cycle at
examination (i.e., if the first day of her last menstruation was no
more than 12 days before). We excluded six girls who had blood
levels of LH higher than 10.0Ul
 1 and/or 17-OH-progesterone
higher than 10.0nmoll
 1, and two girls with abnormally high
levels of progesterone, leaving 62 girls for these hormone-related
analyses.
Testosterone and androstenedione levels were measured by a
double antibody technique on an Elecsys 2010 analyser (Roche
Diagnostics GmbH, Mannheim, Germany). Levels of oestradiol,
progesterone and DHEAS were measured using a competitive
immunoassay on an Immulite 2000 analyser (Diagnostic Products
Corporation, Los Angeles, CA, USA). Levels of SHBG, LH and
prolactin were measured by an immunometric assay on an
Immulite 2000 analyser. Reagents and calibrators supplied by the
manufacturers were used. 17-OH-Progesterone levels were mea-
sured using radioimmunoassay technique with reagents and
calibrators supplied by Orion Diagnostica (Espoo, Finland). The
lower and upper reference values for women were 0.9 and
11.7mmoll
 1 for DHEAS, 0.7 and 11.0nmoll
 1 for androstene-
dione, 0.1 and 2.9nmoll
 1 for testosterone and 1.5 and
12.8nmoll
 1 for 17-OH-progesterone. The lower detection limits
were 0.6nmoll
 1 for progesterone, 0.8mmoll
 1 for DHEAS and
0.1nmoll
 1 for testosterone. The lower and upper detection limits
were 0.07 and 7.34nmoll
 1 for oestradiol, 3 and 180nmoll
 1 for
SHBG, 0.05 and 200.00mIUl
 1 for LH and 11 and 3180mIUl
 1 for
prolactin. For each hormone, analyses were performed in a single
kit on the same day. For girls with levels of progesterone,
oestradiol or DHEAS below the detection limit, levels were set to
0.1nmoll
 1, 0.01nmoll
 1 and 0.1mmoll
 1, respectively.
Statistical analysis
Median age at menarche for each birth size group was estimated by
Kaplan–Meier survival analysis and multivariable analysis was
performed using Cox regression. Differences in adolescent body
size and hormone levels between groups according to birth size,
and linear trends across birth size categories, were evaluated using
general linear modelling. Mean values with 95% confidence
intervals (CI) within each birth size category are reported. In the
hormone analyses, we used logarithmic transformation, as these
variables were not normally distributed, and geometric means are
therefore reported.
We evaluated potential confounding by BMI and age in
adolescence, maternal age at menarche and residential area
(Trondheim or Bergen). All analyses of body size and hormone
levels in adolescence were adjusted for residential region and age
in adolescence. In addition, we adjusted for menarcheal status (pre
or post) in the analyses of adolescent body size and levels of
prolactin and DHEAS. In other hormone analyses, we adjusted for
time as menarche and day of menstrual cycle. All analyses were
adjusted for gestational age. To minimise confounding by the
relatively high prevalence of risk factors for SGA births, we
compared the high-risk group (n¼195) and the random sample
(n¼67) for all variables included using general linear modelling.
We also conducted stratified analyses of these groups for birth size
related to age at menarche, adolescent body size and levels of
prolactin and DHEAS. All statistical analyses were conducted using
the statistical software SPSS for Windows, Release 13.0,
Copyright
r SPSS Inc., 1989–2004 (Chicago, IL, USA).
RESULTS
At examination during adolescence (mean age 14.0 years), 199 out
of 262 girls (76.0%) had reached menarche (Table 1). For all birth
size variables, except ponderal index, girls who were relatively
small at birth were younger at menarche than those with larger
birth size (Table 2). Median age at menarche for girls in the
shortest birth length category (o49.0cm) was 12.5 years (95% CI,
12.26–12.74), compared with 13.3 years (95% CI, 12.95–13.72) for
the highest category (X51.0cm). Similar results were observed for
birth weight, whereas the differences in age at menarche for the
other birth size variables were smaller. Adjustment for potentially
confounding factors did not substantially alter these results (data
not shown).
We found that birth length, weight and head circumference
were positively associated with adolescent height and weight
(Table 2). The associations were further strengthened after
adjustment for age at examination in adolescence, menarcheal
status and geographical region. Comparing the longest and
shortest categories at birth (X51 vs p49cm), the longest were
on average 6.2cm taller (164.6 vs 158.4cm) and 4.2kg heavier
(55.0 vs 50.8kg) in adolescence. Girls in the heaviest birth
category (X3700g) were 4.4cm taller and 4.7kg heavier in
adolescence than those with birth weight below 3200g. For
ponderal index, there was a negative association with adolescent
height; girls who were thin at birth were on average taller in
adolescence, but the association was attenuated after adjustment
for age, menarcheal status and residential region. Girls in the
highest category of birth weight and head circumference had
higher BMI in adolescence compared with girls of average birth
size (Po0.02, results not shown). None of the birth size variables
were related to waist/hip ratio in adolescence, and skin-fold
thickness at birth showed no association with any of the
anthropometric variables in adolescence (data not shown).
Adjustment for gestational age had no influence on the observed
associations (results not shown).
A negative association between head circumference at birth and
circulating level of prolactin in adolescence (P-trend¼0.03) was
attenuated after adjustment for age at puberty, menarcheal status
and residential region (P-trend¼0.12) (Table 3). For other birth
size factors, we found no relation with prolactin. There was a
significant negative association between birth weight, head
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levels of DHEAS in adolescence (i.e. lower DHEAS levels with
increasing size), unaffected by adjustment for the above factors.
Mean (geometric) DHEAS for adolescent girls in the highest birth
weight category was 1.95mmoll
 1 (95% CI, 1.64–2.32) compared
with 2.28mmoll
 1 (95% CI, 1.88–2.78) for the lowest category of
birth weight.
For girls who were in the follicular phase of the menstrual cycle
(Table 4), we found no evidence for any association between birth
size and FTI or level of androstenedione in adolescence. For
oestradiol, there was a tendency for a weak positive association
with all factors of birth size, but significant only for subscapular
skin-fold thickness. Adjustment for age at examination, time since
menarche and region did not substantially influence these
estimates, whereas adjustment for day of menstrual cycle
reinforced them.
Comparing girls from the random sample with those whose
mothers had higher risk of delivering an SGA child, we found no
difference for any of the variables (all P-values 40.1, results not
shown). Stratified analyses of these groups showed similar results
as the overall analyses.
DISCUSSION
In this study of 262 girls who were followed from birth to
adolescence, those whose birth weight, length and head circum-
ference were relatively high had later age at menarche, higher
weight and they were taller in adolescence than those with
relatively small birth size. In relation to circulating hormone levels
in adolescence, greater birth size was associated with relatively
lower DHEAS levels; adolescent levels of oestradiol were weakly
associated with birth size. For other hormones, we found no clear
association with birth size.
Strengths of the present study include the various measures of
anthropometry at birth and in adolescence, all standardized and
Table 1 Mean values (s.d.), minimum and maximum values and number
of missing values of selected variables among 262 Norwegian girls
Variables Mean (s.d.) Range Missing (n)
At birth
Birth weight (g) 3463 (476) 2420–4710 0
Birth length (cm) 50.0 (1.8) 42.0–55.8 3
Ponderal index (gcm
 3) 2.76 (0.26) 2.09–4.18 3
Head circumference (cm) 34.8 (1.2) 31.9–38.0 2
Skin-fold thickness (mm) 4.4 (1.0) 2.2–7.9 3
Gestational age (days) 282.6 (7.1) 264.0–294.0 0
In adolescence
Age (years) 14.0 (0.7) 12.7–15.5 0
Weight (kg) 54.5 (9.9) 33.9–96.4 2
Height (cm) 162.9 (6.8) 143.0–183.5 1
BMI (kg/m
2) 20.5 (3.0) 14.3–32.0 2
Waist/hip ratio 0.78 (0.06) 0.63–1.26 1
Age at menarche (years)
a 13.1 (0.1) 9.5–14.5 6
Maternal
Age at menarche (years) 13.0 (1.4) 10.0–17.0 0
aMedian age at menarche (standard error), calculated by the use of Kaplan–Meier
survival analysis.
Table 2 Adolescent anthropometric measures and age at menarche by birth size among 262 Norwegian girls
Mean
a (95% CI)
Median (95% CI)
Variables No. of girls Height (cm) Weight (kg) Age at menarche (years)
Birth length (cm)
o49.0 84 158.4 (157.0–159.7) 50.8 (48.6–53.0) 12.50 (12.26–12.74)
49.0–51.0 84 160.8 (159.5–162.1) 51.7 (49.6–53.8) 13.08 (12.94–13.22)
X51.0 91 164.6 (163.4–165.8) 55.0 (53.1–56.9) 13.33 (12.95–13.72)
Trend test
b b¼3.13, Po0.001 b¼2.12, P¼0.003 Po0.001
Birth weight (g)
o3200 80 159.9 (158.5–161.4) 51.8 (49.6–53.9) 12.58 (12.32–12.84)
3200–3700 101 160.4 (159.2–161.7) 50.0 (48.1–51.9) 13.25 (12.94–13.56)
X3700 81 164.3 (162.9–165.6) 56.5 (54.5–58.5) 13.33 (12.97–13.70)
Trend test
b b¼2.16, Po0.001 b¼2.37, P¼0.001 P¼0.001
Ponderal index (gcm
 3)
o2.63 83 162.4 (160.9–163.8) 52.7 (50.5–54.8) 12.83 (12.53–13.14)
2.63–2.85 93 161.8 (160.4–163.2) 52.0 (50.0–54.1) 13.08 (12.82–13.35)
X2.85 83 160.8 (159.3–162.2) 53.6 (51.5–55.8) 13.17 (12.68–13.65)
Trend test
b b¼ 0.81, P¼0.098 b¼0.47, P¼0.52 P¼0.099
Head circumference (cm)
o34.2 86 160.5 (159.0–161.9) 51.9 (49.8–54.0) 12.83 (12.42–13.25)
34.2–35.4 92 160.8 (159.5–162.1) 51.0 (49.0–52.9) 13.42 (13.03–13.81)
X35.4 82 163.4 (162.0–164.8) 55.2 (53.2–57.3) 13.17 (12.62–13.71)
Trend test
b b¼1.45, P¼0.003 b¼1.66, P¼0.020 P¼0.003
Skin-fold thickness (mm)
o3.8 88 161.5 (160.0–162.9) 52.2 (50.1–54.4) 12.83 (12.53–13.13)
3.8–4.8 88 161.3 (159.9–162.7) 52.5 (50.4–54.5) 12.92 (12.46–13.37)
X4.8 83 161.9 (160.4–163.3) 53.2 (51.1–55.3) 13.50 (13.07–13.93)
Trend test
b b¼0.18, P¼0.72 b¼0.50, P¼0.49 P¼0.001
CI¼confidence interval.
aAdjusted for age at puberty, menarche status and region.
bRegression coefficient, b, denoting increase in adolescent size measure with increasing birth
size category and corresponding P-value.
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potential confounders such as maternal age at menarche and cyclic
variation of hormone levels. Girls who had reached menarche were
examined shortly after their first menstrual period, reducing
possible recall bias. The modest number of participants is a
limitation of the study. For hormone analyses among girls who
were in the follicular phase of the menstrual cycle, this reduced the
precision of the results.
Our results support the previously reported positive associations
of birth size (either birth weight or length), with age at menarche
(Adair, 2001; Sloboda et al, 2007) and adolescent weight and height
(Pietila ¨inen et al, 2001; Romundstad et al, 2003), and indicate that
the associations may also extend to additional measures of birth
size such as head circumference and skin-fold thickness.
Previous studies indicate that SGA children have higher levels of
DHEAS before adrenarche (Dahlgren et al, 1998), during
adolescence (Ibanez et al, 1999) and in early adulthood (Szathmari
et al, 2001). An inverse relation of birth size with adrenal androgen
levels in 8-year-old children has also been found for children of
normal birth size (Ong et al, 2004). In a recent study of hormone
levels in premenopausal women, there was a suggestive inverse
association of birth weight with DHEAS (Tworoger et al, 2006),
with which our adolescent DHEAS findings accord. Furthermore, it
strengthens the evidence that it is valid for all birth size, and not
only for SGA children.
Circulating levels of DHEAS increase during foetal life, but
decline rapidly after birth and remain low during early childhood,
gradually increasing from about the age of 6 years (adrenarche)
through puberty and reaching a peak in early adult life, followed
by a continuous decline with age (Auchus and Rainey, 2004).
Dehydroepiandrosterone sulphate can be converted both to more
potent androgens and to oestrogens (Ibanez et al, 2000; Nicolas
Diaz-Chico et al, 2007), but its physiological role is unclear and has
been hypothesised to depend on the hormonal milieu (Ebeling and
Koivisto, 1994). The physiological triggers of adrenarche and
adrenal androgen production are unknown, although there are
indications that ACTH, insulin, IGF-I and leptin may be implicated
(Ibanez et al, 2000).
Our findings could be interpreted both as further indications
of the earlier maturation previously reported in children of
small birth size and as a potentially lifelong influence of
developmental plasticity on adrenal androgen production. The
increase in concentration of DHEAS parallels the increase
in skeletal age through puberty (Ibanez et al, 2000). Thus, adrenal
androgen production may contribute to the relation between
birth size and adolescent height, as small birth size is associated
with both higher DHEAS levels and a lower adolescent and final
height.
Oestrogens are believed to be involved in BC development, both
prenatally (Trichopoulos, 1990) and later in life (ESHRE Capri
Workshop Group, 2004). We observed a weak tendency for a
positive association between birth size and adolescent oestradiol
level. In two previous studies, both of which controlled for cyclic
variation, positive associations of premenopausal oestradiol levels
with ponderal index at birth (Jasienska et al, 2006) and birth
weight (Tworoger et al, 2006) were reported. If this relation is true,
it may be in accord with the positive association of birth size with
BC risk observed in many studies.
Longitudinal growth in childhood may be positively associated
with subsequent BC risk (De Stavola et al, 2004), and the
association may be independent of birth weight (Ahlgren et al,
2004; dos Santos Silva et al, 2004). High childhood growth rate is
also associated with earlier age at menarche (Sloboda et al, 2007),
and childhood growth patterns influence the association between
birth size and age at menarche (Adair, 2001; dos Santos Silva et al,
2002). A large population-based study from Denmark (Ahlgren
et al, 2004) found no effect of age at menarche on BC risk after
adjustment for childhood growth patterns.
There are only weak indications that the inverse relation of birth
size with adrenal androgen production in childhood and
adolescence continues into adulthood (Szathmari et al, 2001;
Tworoger et al, 2006). However, should it do so, this would be in
conflict with the association between BC risk and the levels of
adrenal androgens in adulthood (Kaaks et al, 2005a,b), as a
smaller birth size is associated with reduced risk. As for age at
menarche, opposing influences of birth size and childhood growth,
weight gain and overweight have also been reported for adrenal
androgen production in children (Ong et al, 2004), indicating that
the combined pattern of prenatal and postnatal growth may define
the subsequent risk profile.
In conclusion, relatively low birth size was associated with
earlier age at menarche and larger body size in adolescence, but
negatively related to adolescent DHEAS level. The results
demonstrate a link between prenatal factors and subsequent
growth and development.
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Table 3 Adolescent hormone levels by birth size among 262 Norwegian
girls
Geometric mean
a (95 % CI)
Variables
No. of
girls Prolactin (mIUl
 1) DHEAS (lmoll
 1)
Birth length (cm)
o49.0 84 179.9 (162.1–199.6) 2.28 (1.88–2.78)
49.0–51.0 84 206.1 (186.9–227.3) 2.09 (1.73–2.51)
X51.0 91 176.8 (161.1–193.9) 1.95 (1.64–2.32)
Trend test
b e
b¼0.99, P¼0.74 e
b¼0.92, P¼0.21
Birth weight (g)
o3200 80 184.6 (165.7–205.6) 2.51 (2.06–3.05)
3200–3700 101 188.7 (171.8–207.3) 2.08 (1.75–2.46)
X3700 81 186.6 (168.6–206.5) 1.83 (1.52–2.20)
Trend test
b e
b¼1.01, P¼0.88 e
b¼0.85, P¼0.015
Ponderal index (gcm
 3)
o2.63 83 180.5 (163.3–199.6) 2.25 (1.86–2.71)
2.63–2.85 93 197.6 (179.8–217.2) 2.16 (1.81–2.58)
X2.85 83 181.7 (164.1–201.2) 1.84 (1.52–2.23)
Trend test
b e
b¼1.00, P¼0.90 e
b¼0.91, P¼0.13
Head circumference (cm)
o34.2 86 195.5 (176.2–216.9) 2.47 (2.03–2.99)
34.2–35.4 92 188.4 (171.5–207.1) 2.03 (1.70–2.42)
X35.4 82 175.7 (159.3–193.9) 1.92 (1.60–2.30)
Trend test
b e
b¼0.95, P¼0.12 e
b¼0.88, P¼0.047
Skin-fold thickness (mm)
o3.8 88 194.7 (175.6–215.9) 2.41 (2.00–2.91)
3.8–4.8 88 181.8 (164.7–200.6) 2.19 (1.83–2.62)
X4.8 83 185.5 (167.2–205.8) 1.73 (1.43–2.09)
Trend test
b e
b¼0.98, P¼0.48 e
b¼0.85, P¼0.012
CI¼confidence interval; DHEAS¼dehydroepiandrosterone sulphate.
aAdjusted for
age at puberty, menarche status and region.
be
b 100% equals percent change in
hormone levels with increasing birth size category and corresponding P-value.
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